Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2–, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma Meeting Abstract
| Authors: | Ajani, J. A.; Lordick, F.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; Pazo Cid, R. A.; Kang, Y. K.; Yang, J.; Moran, D.; Bhattacharya, P.; Matsangou, M.; Arozullah, A.; Park, J. W.; Shitara, K. |
| Abstract Title: | Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2–, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1322 |
| Language: | English |
| ACCESSION: | WOS:001087480203569 |
| DOI: | 10.1016/j.annonc.2023.10.083 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA82 -- Source: Wos |
